JP2016210798A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016210798A5 JP2016210798A5 JP2016162881A JP2016162881A JP2016210798A5 JP 2016210798 A5 JP2016210798 A5 JP 2016210798A5 JP 2016162881 A JP2016162881 A JP 2016162881A JP 2016162881 A JP2016162881 A JP 2016162881A JP 2016210798 A5 JP2016210798 A5 JP 2016210798A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- excipient
- dopamine
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 4
- 208000004547 Hallucinations Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 2
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 claims 2
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000002532 enzyme inhibitor Substances 0.000 claims 2
- YZZVIKDAOTXDEB-JTQLQIEISA-N nepicastat Chemical compound NCC1=CNC(=S)N1[C@@H]1CC2=CC(F)=CC(F)=C2CC1 YZZVIKDAOTXDEB-JTQLQIEISA-N 0.000 claims 2
- 229950005868 nepicastat Drugs 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 claims 1
- 102000035038 5-HT1 receptors Human genes 0.000 claims 1
- 108091005478 5-HT1 receptors Proteins 0.000 claims 1
- 108050002825 5-Hydroxytryptamine 1A receptors Proteins 0.000 claims 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 1
- 241001514645 Agonis Species 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 229940122459 Glutamate antagonist Drugs 0.000 claims 1
- 229940122439 Hydroxylase inhibitor Drugs 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 claims 1
- 208000001431 Psychomotor Agitation Diseases 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- -1 catechol -O- methyl Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000001272 cocaine abuse Diseases 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 235000019788 craving Nutrition 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 239000003825 glutamate receptor antagonist Substances 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000004050 mood stabilizer Substances 0.000 claims 1
- 229940127237 mood stabilizer Drugs 0.000 claims 1
- 230000008450 motivation Effects 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 claims 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000012034 trail making test Methods 0.000 claims 1
- 239000003558 transferase inhibitor Substances 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93532307P | 2007-08-06 | 2007-08-06 | |
| US60/935,323 | 2007-08-06 | ||
| US95655507P | 2007-08-17 | 2007-08-17 | |
| US60/956,555 | 2007-08-17 | ||
| US96059107P | 2007-10-04 | 2007-10-04 | |
| US60/960,591 | 2007-10-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014107381A Division JP2014148551A (ja) | 2007-08-06 | 2014-05-23 | 依存症治療方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018108758A Division JP2018154645A (ja) | 2007-08-06 | 2018-06-06 | 依存症治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016210798A JP2016210798A (ja) | 2016-12-15 |
| JP2016210798A5 true JP2016210798A5 (enExample) | 2017-06-15 |
Family
ID=40341713
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520285A Pending JP2010535801A (ja) | 2007-08-06 | 2008-08-06 | 依存症治療方法 |
| JP2014107381A Pending JP2014148551A (ja) | 2007-08-06 | 2014-05-23 | 依存症治療方法 |
| JP2016162881A Pending JP2016210798A (ja) | 2007-08-06 | 2016-08-23 | 依存症治療方法 |
| JP2018108758A Pending JP2018154645A (ja) | 2007-08-06 | 2018-06-06 | 依存症治療方法 |
| JP2020081105A Pending JP2020114883A (ja) | 2007-08-06 | 2020-05-01 | 依存症治療方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520285A Pending JP2010535801A (ja) | 2007-08-06 | 2008-08-06 | 依存症治療方法 |
| JP2014107381A Pending JP2014148551A (ja) | 2007-08-06 | 2014-05-23 | 依存症治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018108758A Pending JP2018154645A (ja) | 2007-08-06 | 2018-06-06 | 依存症治療方法 |
| JP2020081105A Pending JP2020114883A (ja) | 2007-08-06 | 2020-05-01 | 依存症治療方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20090041800A1 (enExample) |
| EP (2) | EP3251670A1 (enExample) |
| JP (5) | JP2010535801A (enExample) |
| CN (2) | CN106983747A (enExample) |
| AU (1) | AU2008283903B2 (enExample) |
| BR (1) | BRPI0815089A2 (enExample) |
| CA (1) | CA2695372C (enExample) |
| CO (1) | CO6260015A2 (enExample) |
| ES (1) | ES2638190T3 (enExample) |
| IL (1) | IL257418A (enExample) |
| MX (4) | MX391921B (enExample) |
| NZ (1) | NZ583192A (enExample) |
| PH (1) | PH12015502210A1 (enExample) |
| RU (1) | RU2491067C2 (enExample) |
| SG (2) | SG10201705968RA (enExample) |
| WO (1) | WO2009021055A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201705968RA (en) * | 2007-08-06 | 2017-08-30 | Biotie Therapies Inc | Methods for treating dependence |
| WO2010124089A2 (en) * | 2009-04-22 | 2010-10-28 | Synosia Therapeutics, Inc. | Methods for treating dependence |
| US9804149B2 (en) * | 2012-10-10 | 2017-10-31 | Bio-Rad Laboratories, Inc. | Patient-based results display |
| AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| EP3082816B1 (en) | 2013-12-20 | 2019-03-20 | Indivior UK Limited | Intranasal naloxone compositions and methods of making and using same |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
| US20170235908A1 (en) * | 2015-11-15 | 2017-08-17 | Oriah Behaviorial Health, Inc. | Systems and Methods for Managing and Treating Substance Abuse Addiction |
| AU2018319592B2 (en) | 2017-08-20 | 2024-06-27 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| CN108066355A (zh) * | 2017-12-28 | 2018-05-25 | 宁夏恩多芬科技有限公司 | Nitrous Oxide作为治疗神经官能症的用途 |
| FR3093419B1 (fr) * | 2019-03-08 | 2021-06-18 | Univ Grenoble Alpes | Composition et procédé associé de mesure de l’observance thérapeutique |
| JP2022529781A (ja) | 2019-04-17 | 2022-06-24 | コンパス パスファインダー リミテッド | サイロシビンによるうつ病及び他の様々な障害の治療 |
| EP4180037A1 (en) * | 2019-11-07 | 2023-05-17 | Small Pharma Ltd | Method of synthesis |
| US11806320B2 (en) | 2020-02-19 | 2023-11-07 | Endo Ventures Limited | Isoproterenol compositions and methods |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| CN116528747A (zh) * | 2020-08-17 | 2023-08-01 | 纽约市哥伦比亚大学理事会 | 神经黑色素敏感性mri作为多巴胺功能的生物标志物的用途 |
| JP7753359B2 (ja) * | 2020-10-24 | 2025-10-14 | ユニヴェルシテートスピタル バーゼル | ヒト血漿中のリゼルギン酸ジエチルアミド（ｌｓｄ）及び２，３－ジヒドロ－３－ヒドロキシ－２－オキソリセルギド（ｏ－ｈ－ｌｓｄ）を定量化するための方法 |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| CN112690771B (zh) * | 2020-12-09 | 2022-05-24 | 华南理工大学 | 一种利用线性回归模型的人脸视频心率检测方法 |
| MX2023009703A (es) | 2021-03-11 | 2023-08-29 | Terran Biosciences Inc | Sistemas, dispositivos y metodos para la armonizacion de conjuntos de datos de imaginologia, que incluye biomarcadores. |
| CN113017632B (zh) * | 2021-03-17 | 2022-11-11 | 陈思 | 一种智慧校园心理咨询辅助方法及系统 |
| EP4486448A1 (en) | 2022-03-04 | 2025-01-08 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| IL319304A (en) | 2022-09-16 | 2025-04-01 | Jiangsu Yahong Meditech Co Ltd | Polymorphic form of addition salt of nafixit acid, method for its preparation and use |
| WO2024178082A2 (en) * | 2023-02-22 | 2024-08-29 | Freedom Biosciences, Inc. | Composition of opioid receptor modulator and mdma for use thereof |
| CN120754106B (zh) * | 2025-09-02 | 2025-12-09 | 合肥工业大学 | 化合物sch23390在制备治疗铅中毒药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE91891T1 (de) * | 1987-10-07 | 1993-08-15 | Matrix Technologies Inc | Pharmazeutische zusammensetzung fuer die behandlung der kokainsucht. |
| US5593367A (en) * | 1995-08-18 | 1997-01-14 | Deere & Company | Switchable ignition and starter control system |
| CA2247468A1 (en) * | 1996-02-23 | 1997-08-28 | Mark Froimowitz | Selective d1 dopamine receptor agonists and partial agonists/antagonists |
| US5958896A (en) * | 1997-08-08 | 1999-09-28 | The Mclean Hospital | Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| ATE338575T1 (de) * | 2001-01-17 | 2006-09-15 | Hythiam Inc | Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit |
| WO2002072006A2 (en) * | 2001-03-07 | 2002-09-19 | The Mclean Hospital Corporation | METHODS AND REAGENTS FOR IDENTIFYING COMPOUNDS AND MUTATIONS THAT MODULATE DOPAMINE β-HYDROXYLASE ACTIVITY |
| SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| WO2004075916A1 (en) * | 2003-02-27 | 2004-09-10 | Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. | Pharmaceutical composition for treatment of drug dependence |
| RU2252756C1 (ru) * | 2003-12-23 | 2005-05-27 | Хохлов Александр Петрович | Препарат против алкоголизма и наркомании, способ получения такого препарата |
| AU2008229203B2 (en) * | 2007-03-16 | 2014-05-29 | Emory University | Methods and compositions for treatment of drug addiction |
| US20090054414A1 (en) * | 2007-07-23 | 2009-02-26 | Synosia Therapeutics | Rufinamide for the Treatment of Post-Traumatic Stress Disorder |
| EP2182803A4 (en) * | 2007-07-23 | 2010-09-01 | Synosia Therapeutics | (4-METHOXY-7-MORPHOLIN-4-YL-BENZOTHIAZOL-2-YL) -AMIDE 4-HYDROXY-4-METHYL-PIPERIDINE-1-CARBOXYLIC ACID FOR TREATING POST-TRAUMATIC STRESS DISORDER |
| SG183069A1 (en) * | 2007-07-23 | 2012-08-30 | Synosia Therapeutics | Treatment of post-traumatic stress disorder |
| SG10201705968RA (en) | 2007-08-06 | 2017-08-30 | Biotie Therapies Inc | Methods for treating dependence |
| WO2009069669A1 (ja) | 2007-11-26 | 2009-06-04 | Bridgestone Corporation | 銅－亜鉛合金電気めっき浴およびこれを用いためっき方法 |
-
2008
- 2008-08-06 SG SG10201705968RA patent/SG10201705968RA/en unknown
- 2008-08-06 RU RU2010108249/15A patent/RU2491067C2/ru active
- 2008-08-06 WO PCT/US2008/072357 patent/WO2009021055A1/en not_active Ceased
- 2008-08-06 MX MX2018008628A patent/MX391921B/es unknown
- 2008-08-06 JP JP2010520285A patent/JP2010535801A/ja active Pending
- 2008-08-06 CN CN201611204491.7A patent/CN106983747A/zh active Pending
- 2008-08-06 EP EP17165804.0A patent/EP3251670A1/en not_active Withdrawn
- 2008-08-06 ES ES08797300.4T patent/ES2638190T3/es active Active
- 2008-08-06 AU AU2008283903A patent/AU2008283903B2/en not_active Ceased
- 2008-08-06 CN CN200880109939A patent/CN101815438A/zh active Pending
- 2008-08-06 MX MX2010001390A patent/MX2010001390A/es not_active Application Discontinuation
- 2008-08-06 SG SG2012058210A patent/SG183696A1/en unknown
- 2008-08-06 EP EP08797300.4A patent/EP2182804B1/en not_active Not-in-force
- 2008-08-06 BR BRPI0815089-3A2A patent/BRPI0815089A2/pt not_active IP Right Cessation
- 2008-08-06 CA CA2695372A patent/CA2695372C/en not_active Expired - Fee Related
- 2008-08-06 US US12/187,166 patent/US20090041800A1/en not_active Abandoned
- 2008-08-06 NZ NZ583192A patent/NZ583192A/en not_active IP Right Cessation
- 2008-08-06 MX MX2015009454A patent/MX357542B/es unknown
-
2010
- 2010-02-04 MX MX2022001510A patent/MX2022001510A/es unknown
- 2010-02-26 CO CO10023191A patent/CO6260015A2/es not_active Application Discontinuation
-
2013
- 2013-12-06 US US14/099,882 patent/US10561638B2/en not_active Expired - Fee Related
-
2014
- 2014-05-23 JP JP2014107381A patent/JP2014148551A/ja active Pending
-
2015
- 2015-09-22 PH PH12015502210A patent/PH12015502210A1/en unknown
-
2016
- 2016-08-23 JP JP2016162881A patent/JP2016210798A/ja active Pending
-
2018
- 2018-02-08 IL IL257418A patent/IL257418A/en unknown
- 2018-06-06 JP JP2018108758A patent/JP2018154645A/ja active Pending
-
2020
- 2020-01-07 US US16/736,609 patent/US20200383951A1/en not_active Abandoned
- 2020-05-01 JP JP2020081105A patent/JP2020114883A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Henter et al. | Novel glutamatergic modulators for the treatment of mood disorders: current status | |
| Marcinkowska et al. | Management of dementia-related psychosis, agitation and aggression: a review of the pharmacology and clinical effects of potential drug candidates | |
| Cardinali et al. | Melatonin and its analogs in insomnia and depression | |
| Kulkarni et al. | On the mechanism of antidepressant-like action of berberine chloride | |
| Goldenberg | Medical management of Parkinson’s disease | |
| Bellingham et al. | Duloxetine: a review of its pharmacology and use in chronic pain management | |
| JP2010535801A5 (enExample) | ||
| BRPI0712994A2 (pt) | uso de derivados de alfa-aminoamida úteis no tratamento de distúrbios cognitivos | |
| US11826321B2 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| US12521374B1 (en) | Combination therapy for a dopamine agonist | |
| JP2021080288A (ja) | 吃音を治療するための融合ベンズアゼピン | |
| JP6355921B2 (ja) | コカイン嗜癖の治療 | |
| Kirwin et al. | Duloxetine: A dual serotonin‐norepinephrine reuptake inhibitor for treatment of major depressive disorder | |
| Celikyurt et al. | Serotonin noradrenaline reuptake inhibitors (SNRIs) | |
| Cai et al. | Potential anti-depressive treatment maneuvers from bench to bedside | |
| Ding et al. | Ketamine as a rapid-acting antidepressant: A scoping review of mechanisms and efficacy in treatment-resistant depression | |
| Majid et al. | Therapeutics of narcolepsy | |
| BESHIR et al. | Pharmaceutical sleep medications and medications that affect sleep | |
| TWI922961B (zh) | 用於治療抑鬱症之組合物及方法 | |
| AU2024204318A1 (en) | Treatment of Post-Traumatic Syndrome Disorder | |
| Kominek et al. | Coanalgesic | |
| Soroka et al. | Ketamine in affective disorders–expectations and limitations | |
| HK40116800A (zh) | 用於治疗抑郁的组合物和方法 | |
| Roller et al. | Depression and antidepressants: Through their knowledge of the medications and strategies to manage their condition, pharmacists can play an important role in assisting those patients living with depression to improve their quality of life. | |
| AU2012307535A1 (en) | Combinations comprising a S1P receptor modulator |